Screening	screening	O	O	O	O
for	for	O	O	O	O
stimulant	stimulant	O	O	O	O
use	use	O	O	O	O
in	in	O	O	O	O
adult	adult	O	O	O	O
emergency	emergency	O	O	OTHERS	I
department	department	O	O	OTHERS	I
seizure	seizure	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
objective	objective	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
prevalence	prevalence	O	O	O	O
of	of	O	O	O	O
positive	positive	O	O	O	O
plasma	plasma	O	O	O	O
drug	drug	O	O	O	O
screening	screening	O	O	O	O
for	for	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
adult	adult	O	O	O	O
emergency	emergency	O	O	OTHERS	I
department	department	O	O	OTHERS	I
seizure	seizure	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
This	this	O	O	O	O
prospective	prospective	O	O	O	O
study	study	O	O	O	O
evaluated	evaluated	O	O	O	O
consecutive	consecutive	O	O	O	O
eligible	eligible	O	O	O	O
seizure	seizure	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
plasma	plasma	O	O	O	O
sample	sample	O	O	O	O
collected	collected	O	O	O	O
as	as	O	O	O	O
part	part	O	O	O	O
of	of	O	O	O	O
their	their	O	O	O	O
clinical	clinical	O	O	O	O
evaluation	evaluation	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
was	was	O	O	O	O
tested	tested	O	O	O	O
for	for	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
metabolite	metabolite	O	O	O	O
benzoylecgonine	benzoylecgonine	CHEMICALS	O	OTHERS	I
using	using	O	O	O	O
enzyme-mediated	enzyme-mediated	O	O	O	O
immunoassay	immunoassay	O	O	O	O
methodology	methodology	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
samples	samples	O	O	O	O
with	with	O	O	O	O
benzoylecgonine	benzoylecgonine	CHEMICALS	O	OTHERS	I
greater	greater	O	O	O	O
than	than	O	O	O	O
150	150	O	O	O	O
ng/mL	ng/ml	O	O	O	O
or	or	O	O	O	O
an	an	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
greater	greater	O	O	O	O
than	than	O	O	O	O
500	500	O	O	O	O
ng/mL	ng/ml	O	O	O	O
were	were	O	O	O	O
defined	defined	O	O	O	O
as	as	O	O	O	O
positive	positive	O	O	O	O
.	.	O	O	O	O

Patient	patient	O	O	O	O
demographics	demographics	O	O	O	O
,	,	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
underlying	underlying	O	O	O	O
drug	drug	O	O	O	O
or	or	O	O	O	O
alcohol-related	alcohol-related	O	O	O	O
seizure	seizure	O	DISEASE	OTHERS	I
disorder	disorder	O	O	OTHERS	I
,	,	O	O	O	O
estimated	estimated	O	O	O	O
time	time	O	O	O	O
from	from	O	O	O	O
seizure	seizure	O	DISEASE	OTHERS	I
to	to	O	O	O	O
sample	sample	O	O	O	O
collection	collection	O	O	O	O
,	,	O	O	O	O
history	history	O	O	O	O
or	or	O	O	O	O
suspicion	suspicion	O	O	O	O
of	of	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
abuse	abuse	O	O	OTHERS	I
,	,	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
urine	urine	O	O	O	O
testing	testing	O	O	O	O
for	for	O	O	O	O
drugs	drugs	O	O	O	O
of	of	O	O	O	O
abuse	abuse	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
assay	assay	O	O	O	O
results	results	O	O	O	O
were	were	O	O	O	O
recorded	recorded	O	O	O	O
without	without	O	O	O	O
patient	patient	O	O	O	O
identifiers	identifiers	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Fourteen	fourteen	O	O	O	O
of	of	O	O	O	O
248	248	O	O	O	O
(	(	O	O	O	O
5.6	5.6	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
2.7%-8.5	2.7%-8.5	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
plasma	plasma	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
positive	positive	O	O	O	O
by	by	O	O	O	O
immunoassay	immunoassay	O	O	O	O
testing	testing	O	O	O	O
for	for	O	O	O	O
benzoylecgonine	benzoylecgonine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
no	no	O	O	O	O
samples	samples	O	O	O	O
(	(	O	O	O	O
0	0	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
1.2	1.2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
positive	positive	O	O	O	O
for	for	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Positive	positive	O	O	O	O
test	test	O	O	O	O
results	results	O	O	O	O
were	were	O	O	O	O
more	more	O	O	O	O
common	common	O	O	O	O
in	in	O	O	O	O
patient	patient	O	O	O	O
visits	visits	O	O	O	O
where	where	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
history	history	O	O	O	O
or	or	O	O	O	O
suspicion	suspicion	O	O	O	O
of	of	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
abuse	abuse	O	O	OTHERS	I
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.0005	0.0005	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
During	during	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
period	period	O	O	O	O
,	,	O	O	O	O
routine	routine	O	O	O	O
plasma	plasma	O	O	O	O
screening	screening	O	O	O	O
for	for	O	O	O	O
cocaine	cocaine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
amphetamines	amphetamines	O	O	OTHERS	I
in	in	O	O	O	O
adult	adult	O	O	O	O
seizure	seizure	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
low	low	O	O	O	O
yield	yield	O	O	O	O
.	.	O	O	O	O

As	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
,	,	O	O	O	O
routine	routine	O	O	O	O
plasma	plasma	O	O	O	O
screening	screening	O	O	O	O
would	would	O	O	O	O
yield	yield	O	O	O	O
few	few	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
stimulant	stimulant	O	O	O	O
drug	drug	O	O	O	O
in	in	O	O	O	O
which	which	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
neither	neither	O	O	O	O
a	a	O	O	O	O
history	history	O	O	O	O
nor	nor	O	O	O	O
suspicion	suspicion	O	O	O	O
of	of	O	O	O	O
drug	drug	O	DISEASE	OTHERS	I
abuse	abuse	O	DISEASE	OTHERS	I
in	in	O	O	O	O
this	this	O	O	O	O
population	population	O	O	O	O
.	.	O	O	O	O

